<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00343239</url>
  </required_header>
  <id_info>
    <org_study_id>DOCET_L_00072</org_study_id>
    <nct_id>NCT00343239</nct_id>
  </id_info>
  <brief_title>Docetaxel in Locally Advanced Gastric Adenocarcinoma</brief_title>
  <acronym>NEOTAX</acronym>
  <official_title>Docetaxel, Cisplatin and Fluorouracil Combination in the Neoadjuvant Treatment of Locally Advanced Gastric Adenocarcinoma : Phase II Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Study objectives:

      To determine Ro resection rate of Docetaxel, cisplatin and fluorouracil combination for the
      treatment of neoadjuvant gastric carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the R0 resection rate for the treatment of locally advanced gastric carcinoma with Docetaxel, Cisplatin, Fluorouracil combination.</measure>
    <time_frame>3 cycles</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>Docetaxel/Cisplatin/Fluorouracil (DCF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCF combination for three 21-day cycles unless a disease progression is observed at the tumor assessment scheduled after the second cycle or due to patient intolerability</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Formulation: infusion solution
Route of administration: IV infusion on the first day of each 21-day cycle
Dose regimen: 75 mg/m2</description>
    <arm_group_label>Docetaxel/Cisplatin/Fluorouracil (DCF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Formulation: infusion solution
Route of administration: IV infusion on the first day of each 21-day cycle
Dose regimen: 75 mg/m2</description>
    <arm_group_label>Docetaxel/Cisplatin/Fluorouracil (DCF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Formulation: infusion solution
Route of administration: IV infusion on the first day of each 21-day cycle
Dose regimen: 750 mg/m2/day for 5 days</description>
    <arm_group_label>Docetaxel/Cisplatin/Fluorouracil (DCF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven gastric adenocarcinoma diagnosis

          -  Selected Stage IIB (T3N0M0), Stage IIIA (T2aN2M0, T2bN2M0, T3N1M0, T4N0M0), Stage IIIB
             (T3N2M0) and selected Stage IV (all T4 , NM0, all TN3M0's). Clinical staging performed
             with endoscopic ultrasound and CT. Laparotomy or laparoscopy is preferred to determine
             resectability and peritoneal involvement.

          -  ECOG performance status between 0 and 2

          -  Acceptable hematological profile :

               -  WBC (White Blood Cell) count ≥4000/mm3

               -  Platelet count ≥100 000 mm3

               -  Hemoglobin ≥9 g/100 mL (if lower, may be included following transfusion)

          -  Adequate renal function

               -  Serum creatinine &lt;1.2 mg/dl or calculated creatinine clearance in 24-hours urine
                  &gt;60 mL/min.

          -  Adequate hepatic function

               -  Bilirubin &lt; UNL

               -  Transaminases (ALT, AST) &lt;2.5 x UNL

               -  Alcaline phosphatase &lt;2.5 x UNL

          -  Adequate pulmonary function

          -  Adequate cardiac function

          -  No prior chemotherapy for gastric cancer

        Exclusion Criteria:

          -  Other histological types of gastric cancer (leiomyosarcoma, lymphoma) than
             adenocarcinoma

          -  Pregnant or lactating patients

          -  Patients with brain, bone or other metastases; peritoneal involvement

          -  Other serious underlying medical conditions which could impair the ability of the
             patient to participate in the study (congestive heart failure, serious arrhythmia,
             uncontrolled diabetes mellitus, serious neuropathy), history of myocardial infarction
             within 6 months prior to study entry

          -  Previous or other current malignancies, with the exception of carcinoma of the cervix
             uteri or breast cancer or basal cell skin cancer and a disease-free period shorter
             than 5 years

          -  Active infection and other serious disease

          -  Any other experimental drugs within a 4-week period prior to the study

          -  Contraindications for the use of any study drug (e.g. history of hypersensitivity to
             the contents of the study drugs)

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edibe Taylan</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Ozdemir N, Abali H, Vural M, Yalcin S, Oksuzoglu B, Civelek B, Oguz D, Bostanci B, Yalcin B, Zengin N. Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. Cancer Chemother Pharmacol. 2014 Dec;74(6):1139-47. doi: 10.1007/s00280-014-2586-6. Epub 2014 Sep 19. Erratum in: Cancer Chemother Pharmacol. 2015 Jul;76(1):217.</citation>
    <PMID>25234436</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2006</study_first_submitted>
  <study_first_submitted_qc>June 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2006</study_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

